2020

Varicella Vaccine, Live, was marketed

Quadrivalent Influenza Vaccine was marketed

23-valent Pneumococcal Polysaccharide Vaccine was marketed

Initiated the "Anti-COVID-19 Action" program to R&D Inactivated COVID-19 vaccine, CoronaVac^®, which was one of the first vaccines against COVID-19 in China to be approved for emergency use

SINOVAC's fourth vaccine industrial base in Daxing, Beijing was put into use

Sinovac (Singapore) Ltd. was founded